Skip to main content
Top
Published in: BMC Nephrology 1/2011

Open Access 01-12-2011 | Research article

Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function

Authors: Kisara Onda, Isao Ohsawa, Hiroyuki Ohi, Mariko Tamano, Satoshi Mano, Michiro Wakabayashi, Akie Toki, Satoshi Horikoshi, Teizo Fujita, Yasuhiko Tomino

Published in: BMC Nephrology | Issue 1/2011

Login to get access

Abstract

Background

Glomerular damage in IgA nephropathy (IgAN) is mediated by complement activation via the alternative and lectin pathways. Therefore, we focused on molecules stabilizing and regulating the alternative pathway C3 convertase in urine which might be associated with IgAN pathogenesis.

Methods

Membrane attack complex (MAC), properdin (P), factor H (fH) and Complement receptor type 1 (CR1) were quantified in urine samples from 71 patients with IgAN and 72 healthy controls. Glomerular deposition of C5, fH and P was assessed using an immunofluorescence technique and correlated with histological severity of IgAN and clinical parameters. Fibrotic changes and glomerular sclerosis were evaluated in renal biopsy specimens.

Results

Immunofluorescence studies revealed glomerular depositions of C5, fH and P in patients with IgAN. Urinary MAC, fH and P levels in IgAN patients were significantly higher than those in healthy controls (p < 0.001), but CR1 was significantly lower than that in healthy controls (p < 0.001). Urinary MAC and fH levels were positively correlated with serum creatinine (sCr), urinary N-acetyl-β-D-glucosaminidase (u-NAG), urinary β2 microglobulin (u-Bm), urinary protein (p < 0.001), interstitial fibrosis (MAC: p < 0.01, fH: p < 0.05) and the percentage of global glomerular sclerosis (p < 0.01). Urinary P was positively correlated with u-NAG, u-Bm, and urinary protein (p < 0.01).

Conclusions

Complement activation occurs in the urinary space in IgAN and the measurement of levels of MAC and fH in the urine could be a useful indicator of renal injury in patients with IgAN.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shirai T, Tomino Y, Sato M, Yoshiki T, Itoh T: IgA nephropathy: clinicopathology and immunopathology. Contrib Nephrol. 1978, 9: 88-CrossRefPubMed Shirai T, Tomino Y, Sato M, Yoshiki T, Itoh T: IgA nephropathy: clinicopathology and immunopathology. Contrib Nephrol. 1978, 9: 88-CrossRefPubMed
2.
go back to reference Burkholder PM, Zimmermans SW, Moorthy AV: A clinicopathologic study of natural history of mesangial IgA nephropathy. Glomerulonephritis, Japan Medical Research Foundation Tokyo, Univ. of Tokyo Press. 1979, 143- Burkholder PM, Zimmermans SW, Moorthy AV: A clinicopathologic study of natural history of mesangial IgA nephropathy. Glomerulonephritis, Japan Medical Research Foundation Tokyo, Univ. of Tokyo Press. 1979, 143-
3.
go back to reference Sakai O, Kitajima T, Kawamura K, Ueda Y: Clinicopathological studies on IgA glomerulonephritis. Glomerulonephritis, Japan Medical Research Foundation Tokyo, Univ. of Tokyo Pres. 1979, 167- Sakai O, Kitajima T, Kawamura K, Ueda Y: Clinicopathological studies on IgA glomerulonephritis. Glomerulonephritis, Japan Medical Research Foundation Tokyo, Univ. of Tokyo Pres. 1979, 167-
4.
go back to reference Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T: Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant. 1998, 13: 1984-90. 10.1093/ndt/13.8.1984.CrossRefPubMed Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T: Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant. 1998, 13: 1984-90. 10.1093/ndt/13.8.1984.CrossRefPubMed
5.
go back to reference Endo M, Ohi H, Satomura A, Hidaka M, Ohsawa I, Fujita T, Kanmatsuse K, Matsushita M, Fujita T: Regulation of in situ complement activation via the lectin pathway in patients with IgA nephropathy. Clinical Nephrology. 2001, 55: 185-191.PubMed Endo M, Ohi H, Satomura A, Hidaka M, Ohsawa I, Fujita T, Kanmatsuse K, Matsushita M, Fujita T: Regulation of in situ complement activation via the lectin pathway in patients with IgA nephropathy. Clinical Nephrology. 2001, 55: 185-191.PubMed
6.
go back to reference Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR: Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006, 17: 1724-1734. 10.1681/ASN.2005090923.CrossRefPubMed Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR: Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006, 17: 1724-1734. 10.1681/ASN.2005090923.CrossRefPubMed
7.
go back to reference Roos A, Bouwman LH, Gulswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR: Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001, 167: 2861-2868.CrossRefPubMed Roos A, Bouwman LH, Gulswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR: Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001, 167: 2861-2868.CrossRefPubMed
8.
go back to reference Fearon DT, Austen KF: Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. 1975, 142: 856-863. 10.1084/jem.142.4.856.CrossRefPubMed Fearon DT, Austen KF: Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. 1975, 142: 856-863. 10.1084/jem.142.4.856.CrossRefPubMed
9.
go back to reference Whaley K, Ruddy S: Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science. 1976, 193 (4257): 1011-3. 10.1126/science.948757.CrossRefPubMed Whaley K, Ruddy S: Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science. 1976, 193 (4257): 1011-3. 10.1126/science.948757.CrossRefPubMed
10.
go back to reference Pangburn MK, Schreiber RD, Müller-Eberhard HJ: Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977, 146 (1): 257-70. 10.1084/jem.146.1.257.CrossRefPubMed Pangburn MK, Schreiber RD, Müller-Eberhard HJ: Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977, 146 (1): 257-70. 10.1084/jem.146.1.257.CrossRefPubMed
11.
go back to reference Weiler JM, Daha MR, Austen KF, Fearon DT: Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA. 1976, 73 (9): 3268-72. 10.1073/pnas.73.9.3268.CrossRefPubMedPubMedCentral Weiler JM, Daha MR, Austen KF, Fearon DT: Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA. 1976, 73 (9): 3268-72. 10.1073/pnas.73.9.3268.CrossRefPubMedPubMedCentral
12.
go back to reference Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT: Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med. 1987, 165 (4): 1095-112. 10.1084/jem.165.4.1095.CrossRefPubMed Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT: Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med. 1987, 165 (4): 1095-112. 10.1084/jem.165.4.1095.CrossRefPubMed
13.
go back to reference Miwa T, Song WC: Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol. 2001, 1 (3): 445-59. 10.1016/S1567-5769(00)00043-6.CrossRefPubMed Miwa T, Song WC: Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol. 2001, 1 (3): 445-59. 10.1016/S1567-5769(00)00043-6.CrossRefPubMed
14.
go back to reference Onda K, Ohi H, Tamano M, Ohsawa I, Wakabayashi M, Horikoshi S, Fujita T, Tomino Y: Hypercomplementemia in adult patients with IgA nephropathy. J Clin Lab Anal. 2007, 21: 77-84. 10.1002/jcla.20154.CrossRefPubMed Onda K, Ohi H, Tamano M, Ohsawa I, Wakabayashi M, Horikoshi S, Fujita T, Tomino Y: Hypercomplementemia in adult patients with IgA nephropathy. J Clin Lab Anal. 2007, 21: 77-84. 10.1002/jcla.20154.CrossRefPubMed
15.
go back to reference Ogrodowski JL, Hebert LA, Sedmak D, Cosio FG, Tamerius J, Kolb W: Measurement of SC5b-9 in urine in patients with the nephritic syndrome. Kidney Int. 1991, 40: 1141-1147. 10.1038/ki.1991.326.CrossRefPubMed Ogrodowski JL, Hebert LA, Sedmak D, Cosio FG, Tamerius J, Kolb W: Measurement of SC5b-9 in urine in patients with the nephritic syndrome. Kidney Int. 1991, 40: 1141-1147. 10.1038/ki.1991.326.CrossRefPubMed
16.
go back to reference Tamano M, Fuke Y, Endo M, Ohsawa I, Fujita T, Ohi H: Urinary complement factor H in renal disease. Nephron. 2002, 92: 705-707. 10.1159/000064090.CrossRefPubMed Tamano M, Fuke Y, Endo M, Ohsawa I, Fujita T, Ohi H: Urinary complement factor H in renal disease. Nephron. 2002, 92: 705-707. 10.1159/000064090.CrossRefPubMed
17.
go back to reference Endo M, Fuke Y, Tamano M, Hidaka M, Ohsawa I, Fujita T, Ohi H: Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin Pract. 2004, 97: c147-c153. 10.1159/000079174.CrossRefPubMed Endo M, Fuke Y, Tamano M, Hidaka M, Ohsawa I, Fujita T, Ohi H: Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin Pract. 2004, 97: c147-c153. 10.1159/000079174.CrossRefPubMed
18.
go back to reference Tomino Y, Sakai H: Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003, 7: 93-97. 10.1007/s10157-003-0232-4.CrossRefPubMed Tomino Y, Sakai H: Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol. 2003, 7: 93-97. 10.1007/s10157-003-0232-4.CrossRefPubMed
19.
go back to reference Tamano M, Ohi H, Sudo S, Tomino Y: Quantitative polymorphism of complement receptor type 1 (CR1) in patients undergoing haemodialysis. Nephrol Dial Transplant. 2004, 19 (6): 1467-73. 10.1093/ndt/gfh184.CrossRefPubMed Tamano M, Ohi H, Sudo S, Tomino Y: Quantitative polymorphism of complement receptor type 1 (CR1) in patients undergoing haemodialysis. Nephrol Dial Transplant. 2004, 19 (6): 1467-73. 10.1093/ndt/gfh184.CrossRefPubMed
20.
go back to reference D'amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987, 64: 709-727.PubMed D'amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987, 64: 709-727.PubMed
21.
go back to reference Johnston PA, Brown JS, Braumholtz DA, Davison AM: Clinicopathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry. Q J Med. 1992, 84: 619-627.PubMed Johnston PA, Brown JS, Braumholtz DA, Davison AM: Clinicopathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry. Q J Med. 1992, 84: 619-627.PubMed
22.
go back to reference Julian BA, Wyatt RJ, McMorrow RG, Galla JH: Serum complement proteins in IgA nephropathy. Clin Nephrol. 1983, 20: 251-258.PubMed Julian BA, Wyatt RJ, McMorrow RG, Galla JH: Serum complement proteins in IgA nephropathy. Clin Nephrol. 1983, 20: 251-258.PubMed
23.
go back to reference Zhang JJ, Jiang L, Liu G, Wang SX, Zou WZ, Zhang H, Zhao MH: Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity. Scand J Immunol. 2009, 69 (5): 457-64. 10.1111/j.1365-3083.2009.02234.x.CrossRefPubMed Zhang JJ, Jiang L, Liu G, Wang SX, Zou WZ, Zhang H, Zhao MH: Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity. Scand J Immunol. 2009, 69 (5): 457-64. 10.1111/j.1365-3083.2009.02234.x.CrossRefPubMed
24.
go back to reference Nangaku M, Shankland SJ, Couser WG: Cellular response to injury in membranous nephropathy. J Am Soc Nephrol. 2005, 16 (5): 1195-1204. 10.1681/ASN.2004121098.CrossRefPubMed Nangaku M, Shankland SJ, Couser WG: Cellular response to injury in membranous nephropathy. J Am Soc Nephrol. 2005, 16 (5): 1195-1204. 10.1681/ASN.2004121098.CrossRefPubMed
25.
go back to reference Abbate M, Zoja C, Corna D, Rottoli D, Zanchi C, Azzollini N, Tomasoni S, Berlingeri S, Noris M, Morigi M, Remuzzi : Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. J Am Soc Nephrol. 2008, 19 (6): 1158-67. 10.1681/ASN.2007060686.CrossRefPubMedPubMedCentral Abbate M, Zoja C, Corna D, Rottoli D, Zanchi C, Azzollini N, Tomasoni S, Berlingeri S, Noris M, Morigi M, Remuzzi : Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. J Am Soc Nephrol. 2008, 19 (6): 1158-67. 10.1681/ASN.2007060686.CrossRefPubMedPubMedCentral
26.
go back to reference Cheng ZZ, Corey MJ, Parepalo M, Majno S, Hellwage J, Zipfel PF, Kinders RJ, Raitanen M, Meri S, Jokiranta TS: Complement factor H as a marker for detection of bladder cancer. Clin Chem. 2005, 51: 856-863. 10.1373/clinchem.2004.042192.CrossRefPubMed Cheng ZZ, Corey MJ, Parepalo M, Majno S, Hellwage J, Zipfel PF, Kinders RJ, Raitanen M, Meri S, Jokiranta TS: Complement factor H as a marker for detection of bladder cancer. Clin Chem. 2005, 51: 856-863. 10.1373/clinchem.2004.042192.CrossRefPubMed
27.
go back to reference van den Dobbelsteen ME, Verhasselt V, Kaashoek JG, Timmerman JJ, Schroeijers WE, Verweij CL, van der Woude FJ, van Es LA, Daha MR: Regulation of C3 and factor H synthesis of human glomerular mesangial cells by IL-1 and interferon -gamma. Clin Exp Immunol. 1994, 95: 173-180.CrossRefPubMedPubMedCentral van den Dobbelsteen ME, Verhasselt V, Kaashoek JG, Timmerman JJ, Schroeijers WE, Verweij CL, van der Woude FJ, van Es LA, Daha MR: Regulation of C3 and factor H synthesis of human glomerular mesangial cells by IL-1 and interferon -gamma. Clin Exp Immunol. 1994, 95: 173-180.CrossRefPubMedPubMedCentral
28.
go back to reference Gerritsma JS, Gerritsen AF, De Ley M, van Es LA, Daha MR: Interferon-gamma induces biosynthesis of complement components C2, C4 and factor H by human proximal tubular epithelial cells. Cytokine. 1997, 9: 276-283. 10.1006/cyto.1996.0164.CrossRefPubMed Gerritsma JS, Gerritsen AF, De Ley M, van Es LA, Daha MR: Interferon-gamma induces biosynthesis of complement components C2, C4 and factor H by human proximal tubular epithelial cells. Cytokine. 1997, 9: 276-283. 10.1006/cyto.1996.0164.CrossRefPubMed
29.
go back to reference Iida K, Koyama A, Nakamura H, Inage H, Narita M, Tojyo S, Kamisato J, Fujita T, Tamura N: Abnormal expression of complement receptor (CR1) in IgA nephritis: increase in erythrocytes and loss on glomeruli in patients with impaired renal function. Clin Immunol Immunopathol. 1983, 40: 393-400.CrossRef Iida K, Koyama A, Nakamura H, Inage H, Narita M, Tojyo S, Kamisato J, Fujita T, Tamura N: Abnormal expression of complement receptor (CR1) in IgA nephritis: increase in erythrocytes and loss on glomeruli in patients with impaired renal function. Clin Immunol Immunopathol. 1983, 40: 393-400.CrossRef
30.
go back to reference Moll S, Miot S, Sadallah S, Gudat F, Mihatsch MJ, Schifferli JA: No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int. 2001, 59: 160-168. 10.1046/j.1523-1755.2001.00476.x.CrossRefPubMed Moll S, Miot S, Sadallah S, Gudat F, Mihatsch MJ, Schifferli JA: No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int. 2001, 59: 160-168. 10.1046/j.1523-1755.2001.00476.x.CrossRefPubMed
31.
go back to reference Pascual M, Steiger G, Sadallah S, Paccaud JP, Carpentier JL, James R, Schifferli JA: Identification of Membrane-bound CR1 (CD35) in Human Urine: Evidence for Its Release by Glomerular Podocytes. J Exp Med. 1994, 179: 889-899. 10.1084/jem.179.3.889.CrossRefPubMed Pascual M, Steiger G, Sadallah S, Paccaud JP, Carpentier JL, James R, Schifferli JA: Identification of Membrane-bound CR1 (CD35) in Human Urine: Evidence for Its Release by Glomerular Podocytes. J Exp Med. 1994, 179: 889-899. 10.1084/jem.179.3.889.CrossRefPubMed
Metadata
Title
Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function
Authors
Kisara Onda
Isao Ohsawa
Hiroyuki Ohi
Mariko Tamano
Satoshi Mano
Michiro Wakabayashi
Akie Toki
Satoshi Horikoshi
Teizo Fujita
Yasuhiko Tomino
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2011
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-12-64

Other articles of this Issue 1/2011

BMC Nephrology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.